BRAF (V600E) mutation in isthmic malignant thyroid nodules

被引：3
|
作者：
Campenni, A. [1 ]
Giovanella, L. [2 ,3 ]
Alibrandi, A. [4 ]
Siracusa, M. [1 ]
Ruggeri, R. M. [5 ]
Baldari, S. [1 ]
机构：
[1] Univ Messina, Nucl Med Unit, Dept Biomed Sci & Morphol & Funct Images, Messina, Italy
[2] Oncol Inst So Switzerland, Nucl Med, Bellinzona, Switzerland
[3] Oncol Inst So Switzerland, PET CT Ctr, Bellinzona, Switzerland
[4] Univ Messina, Dept Econ Business & Environm Sci & Quantitat Met, Messina, Italy
[5] Univ Messina, Dept Clin & Expt Med & Pharmacol, Endocrinol Sect, Messina, Italy
来源：
CLINICAL ENDOCRINOLOGY | 2016年 / 84卷 / 01期
关键词：
RISK; ABLATION; CANCER;
D O I：
10.1111/cen.12858
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：152 / 153
页数：3
相关论文
共 50 条
  • [21] Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma
    Jung, Yoon Yang
    Yoo, Jae Hyung
    Park, Eon Sub
    Kim, Mi Kyung
    Lee, Tae Jin
    Cho, Bo Youn
    Chung, Yun Jae
    Kang, Kyung Ho
    Ahn, Hwa Young
    Kim, Hee Sung
    PATHOLOGY RESEARCH AND PRACTICE, 2015, 211 (02) : 162 - 170
  • [22] Correlation between the BRAF V600E mutation status and the clinicopathologic features of papillary thyroid carcinoma
    Shi, C. L.
    Sun, Y.
    Ding, C.
    Lv, Y. C.
    Qin, H. D.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (03) : 7377 - 7385
  • [23] BRAF V600E Mutation Is not Always Present as Expected! A Case Report of Lung and Thyroid Carcinomas
    Piton, Nicolas
    Salaun, Mathieu
    Guisier, Florian
    Marguet, Florent
    Toure, Emmanuel K.
    Gemival, Pierre
    Thiberville, Luc
    Sabourin, Jean-Christophe
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (05) : 897 - 899
  • [24] BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
    Silver, Jennifer A.
    Bogatchenko, Mariya
    Pusztaszeri, Marc
    Forest, Veronique-Isabelle
    Hier, Michael P.
    Yang, Ji Wei
    Tamilia, Michael
    Payne, Richard J.
    JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2021, 50 (01)
  • [25] Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma
    Sun, Jian
    Zhang, Jing
    Lu, Junliang
    Gao, Jie
    Lu, Tao
    Ren, Xinyu
    Duan, Huanli
    Liang, Zhiyong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (11): : 15072 - 15078
  • [26] Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma
    Zhu, Xiaoli
    Luo, Yanli
    Bai, Qianming
    Lu, Yongming
    Lu, Yiqiong
    Wu, Lijing
    Zhou, Xiaoyan
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2016, 100 (01) : 236 - 241
  • [27] Thymic Adenocarcinoma with Positivity for Thyroid Transcription Factor-1 and a BRAF V600E Mutation
    Yorozuya, Takafumi
    Otsuka, Mitsuo
    Ichihara, Shin
    Fujimori, Kento
    Kitamura, Chikako
    Takahashi, Tomoyuki
    Mori, Masaki
    Cho, Yasushi
    Chiba, Hirofumi
    INTERNAL MEDICINE, 2022, 61 (03) : 385 - 388
  • [28] Relationship between BRAF V600E and clinica features in papillary thyroid carcinoma
    Yan, Changjiao
    Huang, Meiling
    Li, Xin
    Wang, Ting
    Ling, Rui
    ENDOCRINE CONNECTIONS, 2019, 8 (07): : 988 - 996
  • [29] Morphology predicts BRAF V600E mutation in papillary thyroid carcinoma: an interobserver reproducibility study
    Virk, Renu K.
    Theoharis, Constantine G. A.
    Prasad, Avinash
    Chhieng, David
    Prasad, Manju L.
    VIRCHOWS ARCHIV, 2014, 464 (04) : 435 - 442
  • [30] Immunohistochemistry is a feasible method to screen BRAF V600E mutation in colorectal and papillary thyroid carcinoma
    Zhang, Xiangyan
    Wang, Lili
    Wang, Jigang
    Zhao, Han
    Wu, Jie
    Liu, Shuhong
    Zhang, Lu
    Li, Yujun
    Xing, Xiaoming
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2018, 105 (01) : 153 - 159
12345